RxMx has been selected as an ABA100® Winner for New Product Innovation in The Australian Business Awards 2021. The Australian Business Award for New Product Innovation [NEW] recognises new products and services that provide innovative solutions for business and market needs launched onto the Australian market after 1st January 2020.

“We’re honored to be ABA100 Winners in the New Product Innovation category along with Novartis for our MSGo product. Together, we’re breaking barriers to help patients and healthcare providers use technology to communicate while creating a safe, streamlined process for a complex medical program. We believe this program is a glimpse into the future and one day all therapies that require monitoring, communication, lab work and tracking adherence will have digital companion apps.”

George Hunnewell, CEO, RxMx

We’re RxMx, a healthcare company with exceptional technology solutions and long standing industry experience. We were founded in 2013 by doctors who refused to accept “business as usual” when prescribing specialty medicines to patients with serious chronic diseases. Since then, we’ve built our business on the idea that by automating certain tasks with technology, we can empower doctors and nurses to safely administer specialty medicines without increasing their burden so they can focus on patient care.

We partnered with Novartis to introduce a digital companion app for patients beginning a complex therapy for a serious chronic disease as well as a portal and app for their prescribing healthcare provider (HCP) teams.

Novartis uses science-based innovation to address some of society’s most challenging healthcare issues. They discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. Their vision is to become the most valued and trusted medicines company in the world.

Our two companies worked together to develop a suite of technology products to support the HCP teams and help patients steamline lab work and medication adherence as they embark on a new therapy created by Novartis. By using the technology developed for the program, patients and HCPs are supported in navigating pre-enrollment tests, the detailed therapy commencement process and ongoing therapy adherence.

To understand the benefits we provide, it is important to understand the typical process a patient goes through without our product in place. Normally a patient would go to a doctor’s office and receive a stack of paperwork containing several lab tests to take and be responsible for navigating through the process on their own. This includes scheduling multiple appointments and ensuring that the doctor’s office receives the results after the tests are complete. Our patient app and nurse team coordinates this time-consuming and often unintuitive process for patients.

In the patient app, patients can view their lab results in real time. Similarly, doctors receive notifications (in real time) to see when lab results are available to review for their patients in the HCP app or portal. Nurses are available to ensure that the patient has a prescription available and will remedy the situation if this isn’t the case.

Not only does our approach support patients throughout the initial testing and monitoring process, it helps them get on to the therapy as soon as possible.

Our program is currently in use in Australia as well as countries in Europe. We have plans to expand into additional countries throughout Europe and into the Middle East in 2021. Our programs comply with the Medicines Australia Code of Conduct and GDPR in Europe.

Share: The Australian Business Awards

Register for Updates

How to Participate in the Awards

Register to download entry guidelines and receive program updates.
Register for Updates